Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $174.1 million.

  • Perspective Therapeutics' Cash & Equivalents fell 3498.88% to $174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.1 million, marking a year-over-year decrease of 3498.88%. This contributed to the annual value of $61.6 million for FY2024, which is 56659.45% up from last year.
  • As of Q3 2025, Perspective Therapeutics' Cash & Equivalents stood at $174.1 million, which was down 3498.88% from $191.6 million recorded in Q2 2025.
  • Perspective Therapeutics' Cash & Equivalents' 5-year high stood at $267.8 million during Q3 2024, with a 5-year trough of $9.2 million in Q4 2023.
  • Over the past 5 years, Perspective Therapeutics' median Cash & Equivalents value was $61.6 million (recorded in 2024), while the average stood at $94.7 million.
  • As far as peak fluctuations go, Perspective Therapeutics' Cash & Equivalents surged by 307989.69% in 2021, and later crashed by 6921.87% in 2022.
  • Perspective Therapeutics' Cash & Equivalents (Quarter) stood at $60.4 million in 2021, then crashed by 65.22% to $21.0 million in 2022, then crashed by 55.99% to $9.2 million in 2023, then soared by 566.59% to $61.6 million in 2024, then skyrocketed by 182.72% to $174.1 million in 2025.
  • Its last three reported values are $174.1 million in Q3 2025, $191.6 million for Q2 2025, and $211.7 million during Q1 2025.